CKChaninan Kositkuljorn

Chaninan Kositkuljorn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chaninan Kositkuljorn has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and Trichoscopic Differentiation of Fibrosing Alopecia in a Pattern Distribution From Female Pattern Hair Loss: A Biopsy‐Confirmed Diagnostic Accuracy Study

    by Korn Triyangkulsri, Chaninan Kositkuljorn, Kanchana Leerunyakul, Suthinee Rutnin, Poonkiat Suchonwanit

    Female pattern hair loss (FPHL) and fibrosing alopecia in a pattern distribution (FAPD) share similar clinical presentations but differ fundamentally in pathophysiology and management. Reliable, noninvasive trichoscopic criteria to distinguish these entities remain inadequately defined. This prospective cross‐sectional study enrolled 63 consecutive women with biopsy‐confirmed patterned alopecia (21 FAPD and 42 FPHL), matched for hair loss severity using the Sinclair scale, to compare clinical and trichoscopic features and develop a hierarchical diagnostic algorithm. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) were calculated with 95% confidence intervals. Loss of follicular ostia was identified in all FAPD cases, but only 2.4% of FPHL cases (AUC 0.99), and white fibrotic patches occurred exclusively in FAPD (47.6%), while yellow dots were found only in FPHL (83.3%). Vellus hairs > 10% were significantly less frequent in FAPD than FPHL (47.6% vs. 95.2%), reflecting a relative vellus hair depletion, termed the “vellus paradox,” likely caused by preferential destruction of miniaturized follicles by the lichenoid inflammatory process. FAPD patients also had shorter disease duration and more frequent scalp symptoms, including burning sensation and tenderness. A hierarchical two‐step trichoscopic algorithm using specificity‐based rule‐in (loss of follicular ostia or white fibrotic patches) and sensitivity‐based rule‐out heuristics (hair diameter diversity or vellus proportion) achieved 100% sensitivity, 97.6% specificity, and 98.4% overall accuracy (AUC 0.99) for identifying FAPD. Distinct trichoscopic features, particularly loss of follicular ostia, white fibrotic patches, and relative vellus hair depletion, reliably differentiate FAPD from FPHL. The proposed algorithm enables rapid, noninvasive bedside diagnosis in this derivation cohort; external validation is required before routine implementation.

  • Open Access

    Differences in Demographic and Clinical Characteristics Among Subtypes of Female Pattern Hair Loss

    by Nawara Sakpuwadol, Kasama Tejapira, Chaninan Kositkuljorn, Cherrin Pomsoong, Poonkiat Suchonwanit

    Background: Female pattern hair loss (FPHL) is the most common hair loss disorder in women that can be classified into three patterns, including Ludwig, Olsen, and Hamilton-Norwood subtypes. Information regarding the comparison of demographics, clinical characteristics, and associated comorbidities among subtypes of FPHL is scarce and contradictory. Objective: To evaluate and compare the epidemiology, clinical manifestations, and comorbid conditions of FPHL subtypes and determine their associated factors. Methods: This retrospective study included patients who were diagnosed with FPHL between January 2000 and November 2021. Participants were classified into three subtypes, namely Ludwig, Olsen, and Hamilton-Norwood, and were statistically compared. Variables significantly associated with each FPHL subtype were identified using multivariable multinomial logistic regression analysis. Results: Among the 519 patients with FPHL, the Ludwig subtype was the most prevalent (51.1%), followed by the Olsen (32.9%) and Hamilton-Norwood (16%) subtypes. The Hamilton-Norwood subtype revealed significantly higher frequencies of early disease onset (61.4%), menstrual irregularity (22.9%), polycystic ovary syndrome (PCOS, 18.1%), and seborrhea (30.1%) but lower frequencies of overweight (24.1%) and type 2 diabetes mellitus (DM, 2.4%). Multivariable multinomial regression analysis demonstrated that the Hamilton-Norwood subtype was a predictor for early disease onset and PCOS compared to Ludwig (early onset: odds ratio (OR) = 2.14, 95% confidence interval (CI) = 1.39– 4.22, P = 0.02; PCOS: OR = 2.02, 95% CI = 1.55– 4.84, P = 0.03), and Olsen (early onset: OR = 1.89, 95% CI = 1.03– 3.92, P = 0.04; PCOS: OR = 2.24, 95% CI = 1.89– 5.31, P = 0.01). In contrast, the Hamilton-Norwood pattern was at decreased risk for type 2 DM compared to Ludwig (OR = 0.51, 95% CI = 0.03– 0.82, P = 0.02), and Olsen (OR = 0.68, 95% CI = 0.04– 0.79, P = 0.03). Conclusion: The Ludwig pattern was found to be the most prevalent FPHL subtype among Thai patients. Moreover, the Hamilton-Norwood subtype was associated with early disease onset and PCOS, whereas the Ludwig and Olsen subtypes were associated with type 2 DM.


  • Open Access

    Characterizing Dermatological Conditions in the Transgender Population: A Cross-Sectional Study

    by Suthinee Rutnin, Poonkiat Suchonwanit, Chaninan Kositkuljorn, Cherrin Pomsoong, Sira Korpaisarn, Jiraporn Arunakul, Teerapong Rattananukrom

    Purpose: This study aimed to demonstrate the effects of gender-affirming hormone therapy (GAHT) and gender-affirming procedures on the skin in transgender individuals. Methods: We conducted a cross-sectional study among transgender people. Skin conditions related to GAHT were assessed, including acne (using the Investigator's Global Assessment, IGA), postacne sequelae, melasma, hypertrichosis in androgen-sensitive areas (HAAs) in transgender men (TM) and hirsutism in transgender women (TW) (using the modified Ferriman–Gallwey score, mFG score), and hair loss (using the Hamilton–Norwood and Ludwig scale) at baseline, 6 months after GAHT, and the day on which the questionnaire was completed. Dermatological problems after gender-affirming procedures were evaluated. Results: A total of 159 patients, including 134 TM and 25 TW, were eligible to participate. The median duration of GAHT was 23 and 36 months in TM and TW, respectively. In TM, the median IGA score of facial acne increased from 1 at baseline to 3 after 6 months and decreased to 2 after 2 years of GAHT. The mFG score indicated HAA in all TMs after testosterone treatment. A total of 88.1% of TM had no hair loss before hormone therapy. However, after 2 years of GAHT, 76.1% of TM developed male pattern hair loss (MPHL), and 26.1% of them had moderate-to-severe MPHL. In TW, the median IGA and mFG scores decreased after 3 years of hormone therapy, and the proportion of female pattern hair loss (FPHL) in TW increased to 16% after GAHT. In both groups, the most common skin complication after gender-affirming surgery was hypertrophic scarring. Conclusions: GAHT in TM resulted in acne and MPHL, whereas GAHT in TW caused melasma and FPHL.


  • Sleep quality in men with androgenetic alopecia

    by Somprasong Liamsombut, Cherrin Pomsoong, Chaninan Kositkuljorn, Kanchana Leerunyakul, Visasiri Tantrakul, Poonkiat Suchonwanit

    Purpose Sleep disturbances affect human health and contribute to several comorbidities. In men, androgenetic alopecia (AGA) is a common, non-scarring form of hair loss that affects a patient’s self-esteem. There are limited data regarding the association between poor sleep quality and male AGA. We aimed to compare the prevalence of sleep abnormalities between male patients with AGA and controls to identify an association between the two conditions. Methods A case–control study on patients with AGA and age-matched controls was conducted. Participants completed a standardized questionnaire that contained self-evaluated sleep measures, including Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, and STOP-BANG questionnaire. Patients with AGA were classified into mild, moderate, and severe subgroups according to the Hamilton-Norwood classification for stratified analyses. Data between groups and among subgroups were compared. Results Of 446 male participants, 223 (50%) were in the AGA group, and the remainder (50%) were in the control group. Multivariable logistic regression analysis revealed that hypertension (odds ratio [OR] = 1.90, 95% confidence interval [CI] = 1.16–3.11, p = 0.011) and STOP-BANG score ≥ 5 (OR = 2.05, 95%CI = 1.15–3.66, p = 0.015) were associated with AGA. For subgroup analyses, ordinal logistic regression model showed a significant association between severe AGA and three sleep profiles, namely total sleep time ≤ 6 h (OR = 2.16, 95%CI = 1.02–4.57, p = 0.044), PSQI > 5 (OR = 3.72, 95%CI = 1.42–9.72, p = 0.008), and STOP-BANG score ≥ 5 (OR = 3.01, 95%CI = 1.11–8.13, p = 0.030). Conclusion Our findings revealed an association between sleep disturbances and AGA, which may help guide appropriate management in these patients.


  • Open Access

    Intramuscular Corticosteroid Therapy in the Treatment of Alopecia Areata: A Time-to-Event Analysis

    by Kumutnart Chanprapaph, Cherrin Pomsoong, Chaninan Kositkuljorn, Poonkiat Suchonwanit

    Introduction: Intramuscular corticosteroids (IMC) have gained popularity for the treatment of severe alopecia areata (AA) in recent years; however, evidence on their efficacy and safety is still limited. Objective: To evaluate the efficacy, relapse rate, and tolerability of IMC in the treatment of AA, as well as factors associated with treatment outcomes. Methods: Time-to-event analysis was performed on patients with severe, extensive, or rapidly progressive AA receiving IMC. The IMC regimen comprised triamcinolone acetonide 20– 40 mg/mL injected every 4– 6 weeks. The evaluated outcomes included initial (25% regrowth), significant (75% regrowth), and complete hair regrowth (100% regrowth). Relapse and adverse events were also noted. Factors associated with treatment outcomes and relapse were analyzed using the Cox proportional hazards model. Results: A total of 101 patients were eligible for analysis. Significant hair regrowth was obtained in 80.2% of the patients (n = 81), in a median time of 3.4 months (95% confidence interval [CI] = 2.9– 4.4). Complete hair regrowth was achieved in 48.5% of the subjects (n = 49), and relapse was observed in 47.5% (n = 48). Acneiform eruption was the most common adverse effect. Multivariable analysis revealed that nail involvement was a negative predictor of significant hair regrowth (adjusted hazard ratio [HR] = 0.04, 95% CI = 0.01– 0.55; P = 0.015), whereas duration of AA longer than 6 months was associated with disease recurrence (adjusted HR = 4.02, 95% CI = 1.52– 4.66; P = 0.005). Conclusion: This study demonstrated the efficacy and safety of IMC in the treatment of severe or active AA; however, the relapse rate remained relatively high after discontinuation of the therapy. Nail involvement was a negative predictor of significant hair regrowth, while disease duration longer than 6 months predicted AA relapse.


  • Open Access

    Alopecia Areata: An Autoimmune Disease of Multiple Players

    by Poonkiat Suchonwanit, Chaninan Kositkuljorn, Cherrin Pomsoong

    Alopecia areata (AA) is an autoimmune disease of the hair follicles. It is characterized by a well-defined non-scarring alopecic patch or patches that may extend to the entire scalp or lead to total body hair loss. Due to its unpredictable clinical course, AA causes substantial psychological harm. Despite the high prevalence of this disease and extensive research, its exact pathomechanism is unclear, and current treatments have a high relapse rate that has deemed AA incurable. Over the past few decades, researchers have investigated multiple potential factors that may help alleviate its pathogenesis and provide effective treatment. Given its complex immunopathogenesis, AA is considered an autoimmune disease with multiple factors. This review gathers current evidence that emphasizes molecular mechanisms, possible causative etiologies, and targeted immunotherapies for AA. Understanding its underlying mechanisms may shed light on new strategies to effectively manage AA in the future.


  • Open Access

    Diagnostic and prognostic values of cutaneous manifestations in COVID ‐19

    by Poonkiat Suchonwanit, Kanchana Leerunyakul, Chaninan Kositkuljorn

    Click on the article title to read more.